Axial Spondyloarthritis: Epidemiology Forecast to 2028

Axial spondyloarthritis (AxSpA) is a condition characterized by predominant inflammation in the spine and/or sacroiliac joints, with inflammatory back pain and stiffness that may be improved with exercise. Based on sacroiliac changes on conventional radiographs, AxSpA is classified into radiographic (r-AxSpA) or nonradiographic (nr-AxSpA) depending on the presence or absence of radiographic changes at the sacroiliac joints. Patients traditionally classified as ankylosing spondylitis (AS) would be considered as r-AxSpA. Some of nr-AxSpA progress to AS and some do not (Sieper et al., 2002; Kiltz et al., 2012; Wallis et al., 2013). AS has a genetic association with the HLA-B27 risk allele (Sieper et al., 2002; Dean et al., 2014).

GlobalData epidemiologists selected nationally representative population-based studies that provided data for the diagnosed prevalence of AxSpA in the 7MM. GlobalData’s epidemiological analysis provides country-specific forecast for the diagnosed prevalent cases of AS and nr-AxSpA in the 7MM during 2018–2028 using two different approaches: forecast based on data obtained through primary market research (PMR) (base scenario), and forecast based on data obtained from secondary research (alternate scenario).

The following data describes diagnosed prevalent cases of AS and nr-AxSpA in the 7MM using base scenario, where the forecast is based on data obtained from PMR. In the 7MM, the diagnosed prevalent cases of AS will increase from 1,393,906 cases in 2018 to 1,788,563 cases in 2028, at an Annual Growth Rate (AGR) of 2.83% and the diagnosed prevalent cases of nr-AxSpA will increase from 1,003,767 cases in 2018 to 1,328,882 cases in 2028, at an AGR of 3.24%.

Scope

The Axial Spondyloarthritis Epidemiology Report and Model provide an overview of the risk factors and global trends of AxSpA in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).

Base Scenario: This report includes a 10-year epidemiological forecast for the diagnosed prevalent cases of AS and nr-AxSpA for both sexes and ages ≥18 years in the 7MM.

Alternate Scenario: Additionally, a 10-year epidemiological forecast for the diagnosed prevalent cases of AS and nr-AxSpA segmented by age (18–19 years, 20–29 years, 30–44 years, 45–59 years, 60–74 years, 75–79 years, 80–84 years, and 85 years and older) and sex. The report also provides the forecast for diagnosed prevalent cases of AS segmented by HLA-B27 seropositivity status in the 7MM.

The axial spondyloarthritis epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.

  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
  • The Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to buy

The AxSpA Epidemiology series will allow you to:

Develop business strategies by understanding the trends shaping and driving the global AxSpA market.

Quantify patient populations in the global AxSpA market to improve product design, pricing, and launch plans.

Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for AxSpA therapeutics in each of the markets covered.

Understand magnitude of AxSpA by radiographic and nonradiographic population.

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Axial Spondyloarthritis: Executive Summary

2.1 Related Reports

2.2 Upcoming Reports

3 Epidemiology ...

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Axial Spondyloarthritis: Executive Summary

2.1 Related Reports

2.2 Upcoming Reports

3 Epidemiology

3.1 Disease Background

3.2 Risk Factors and Comorbidities

3.3 Global and Historical Trends

3.4 Forecast Methodology

3.4.1 Sources

3.4.2 Forecast Assumptions and Methods, Diagnosed Prevalent Cases of AS - Base Scenario

3.4.3 Forecast Assumptions and Methods, Diagnosed Prevalent Cases of Nr-AxSpA - Base Scenario

3.4.4 Forecast Assumptions and Methods, Diagnosed Prevalent Cases of AS - Alternative Scenario

3.4.5 Forecast Assumptions and Methods, Diagnosed Prevalent Cases of Nr-AxSpA - Alternative Scenario

3.4.6 Forecast Assumptions and Methods, HLA-B27 Seropositivity Among Diagnosed AS Patients

3.5 Epidemiological Forecast for AS and Nr-AxSpA (2018–2028) – Base Scenario

3.5.1 Diagnosed Prevalent Cases of AS

3.5.2 Diagnosed Prevalent Cases of Nr-AxSpA

3.6 Epidemiological Forecast for AS and Nr-AxSpA (2018–2028) – Alternative Scenario

3.6.1 Diagnosed Prevalent Cases of AS

3.6.2 Age-Specific Diagnosed Prevalent Cases of AS

3.6.3 Sex-Specific Diagnosed Prevalent Cases of AS

3.6.4 Diagnosed Prevalent Cases of AS by HLA-B27 Seropositivity

3.6.5 Diagnosed Prevalent Cases of Nr-AxSpA

3.6.6 Age-Specific Diagnosed Prevalent Cases of Nr-AxSpA

3.6.7 Sex-Specific Diagnosed Prevalent Cases of Nr-AxSpA

3.7 Discussion

3.7.1 Epidemiological Forecast Insight

3.7.2 Limitations of the Analysis

3.7.3 Strengths of the Analysis

4 Appendix

4.1 Bibliography

4.2 Primary Research – Prescriber Survey

4.3 Abbreviations

4.4 About the Authors

4.4.1 Epidemiologist

4.4.2 Reviewers

4.4.3 Global Director of Therapy Analysis and Epidemiology

4.4.4 Global Head and EVP of Healthcare Operations and Strategy

4.5 About GlobalData

4.6 Contact Us

4.7 Disclaimer

List of Tables

Table 1: Risk Factors and Comorbidities for AS

Table 2: High-Prescribing Physicians (KOL and non-KOLs) Surveyed, By Country

Table 1: Risk Factors and Comorbidities for AS

Table 2: High-Prescribing Physicians (KOL and non-KOLs) Surveyed, By Country

List of Figures

Figure 1: 7MM, Diagnosed Prevalent Cases of AS, All Ages, Both Sexes, N, 2018 and 2028 – Base Scenario

Figure 2: 7MM, Diagnosed Prevalent Cases ...

Figure 1: 7MM, Diagnosed Prevalent Cases of AS, All Ages, Both Sexes, N, 2018 and 2028 – Base Scenario

Figure 2: 7MM, Diagnosed Prevalent Cases of Nr-AxSpA, All Ages, Both Sexes, N, 2018 and 2028 – Base Scenario

Figure 3: 7MM, Diagnosed Prevalence (%) of AxSpA, Both Sexes, Ages ≥18 Years, 2008–2028 – Base Scenario

Figure 4: 7MM, Sources Used, Diagnosed Prevalent Cases of AS – Base Scenario

Figure 5: 7MM, Sources Used, Diagnosed Prevalent Cases of Nr-AxSpA - Base Scenario

Figure 6: 7MM, Sources Used and Not Used, Diagnosed Prevalent Cases of AS – Alternative Scenario

Figure 7: 7MM, Sources Used and Not Used, Diagnosed Prevalent Cases of Nr-AxSpA - Alternative Scenario

Figure 8: 7MM, Sources Used, HLA-B27 Seropositivity Data Among the Diagnosed Prevalent Cases of AS - Alternative Scenario

Figure 9: 7MM, Diagnosed Prevalent Cases of AS, Ages ≥18 Years, Both Sexes, N, 2018 – Base Scenario

Figure 10: 7MM, Diagnosed Prevalent Cases of Nr-AxSpA, Ages ≥18 Years, Both Sexes, N, 2018 – Base Scenario

Figure 11: 7MM, Diagnosed Prevalent Cases of AS, Ages ≥18 Years, Both Sexes, N, 2018 – Alternative Scenario

Figure 12: 7MM, Age-Specific Diagnosed Prevalent Cases of AS, Both Sexes, N, 2018 – Alternative Scenario

Figure 13: 7MM, Sex-Specific Diagnosed Prevalent Cases of AS, Ages ≥18 Years, N, 2018 – Alternative Scenario

Figure 14: 7MM, Diagnosed Prevalent Cases of AS by HLA-B27 Seropositivity, Ages ≥18 Years, Both Sexes, N, 2018 – Alternative Scenario

Figure 15: 7MM, Diagnosed Prevalent Cases of Nr-AxSpA, Ages ≥18 Years, Both Sexes, N, 2018 – Alternative Scenario

Figure 16: 7MM, Age-Specific Diagnosed Prevalent Cases of Nr-AxSpA, Both Sexes, N, 2018 – Alternative Scenario

Figure 17: 7MM, Sex-Specific Diagnosed Prevalent Cases of Nr-AxSpA, Ages ≥18 Years, N, 2018 – Alternative Scenario

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 (0) 161 359 5813

Join our mailing list

Saved reports